Hypothesis\n\nGermline cells keep autophagy high by maintaining a weak BCL-2/Beclin-1 interaction, a state that can be mimicked in somatic cells to improve quality control without relying on enhanced repair. \n\nWe propose that sustained, inducible disruption of the BCL-2/Beclin-1 brake in adult somatic tissues will raise basal autophagic flux, reduce accumulation of damaged mitochondria and protein aggregates, delay senescence markers, and extend median lifespan in mice, while not increasing cancer incidence if the intervention is temporally restricted. \n\n## Mechanistic Rationale\n\nThe F121A mutation in Beclin-1 prevents BCL-2 binding, leaving the Vps34 complex constitutively active 1. Germline cells appear to occupy this state naturally, which supports meiotic fidelity by clearing defective organelles during oocyte maturation 2. In somatic tissues, age‑dependent tightening of the BCL-2/Beclin-1 interaction suppresses autophagy, contributing to organ dysfunction. \n\nIf we replicate the germline‑like low binding condition, we predict:\n- Increased LC3‑II turnover and p62 degradation in treated tissues.\n- Lower levels of γH2AX and 4‑HNE, indicating less DNA and lipid damage.\n- Reduced p16^Ink4a^ and SA‑β‑gal activity, reflecting delayed senescence.\n- Improved functional readouts (e.g., grip strength, treadmill endurance, cardiac ejection fraction).\n- No rise in tumorigenesis when the disruption is limited to post‑mitotic or slowly dividing compartments and turned off after a defined window. \n\n## Experimental Plan\n\n1. Generate a tamoxifen‑inducible, Cre‑dependent F121A Beclin-1 knock‑in mouse line (Rosa26^LSL‑F121A‑Beclin1).\n2. Cross with tissue‑specific Cre lines (e.g., MCM‑Cre for skeletal muscle, αMHC‑Cre for heart, Alb‑Cre for liver).\n3. Administer tamoxifen at 6 months of age for 2 weeks to activate the mutant, then withdraw.\n4. Monitor autophagy flux via lysosomal inhibition assays (chloroquine chase) and immunoblot for LC3‑II/I and p62 at 1, 3, 6 months post‑induction.\n5. Assess senescence (p16^Ink4a^ mRNA, SA‑β‑gal), oxidative stress (4‑HNE, protein carbonyls), and DNA damage (γH2AX foci).\n6. Perform functional assays: grip strength, rotarod, echocardiography, glucose tolerance.\n7. Track survival and cause of death; histologically examine organs for hyperplasia or neoplasia.\n8. As a control, include wild‑type littermates and mice bearing a non‑functional Beclin-1 mutant (e.g., WT knock‑in).\n\n## Expected Outcomes and Falsifiability\n\nIf the hypothesis is correct, induced tissues will show a significant increase in autophagic flux and a concomitant delay in age‑related functional decline compared with controls, without a detectable increase in tumor burden. \nConversely, if autophagy flux does not rise, or if functional benefits are absent, or if accelerated pathology (including cancer) appears, the hypothesis would be falsified. This would indicate that germline‑level autophagy maintenance cannot be transferred to somatic cells by simply weakening the BCL-2/Beclin-1 brake, pointing to additional lineage‑specific regulators.\n\n## Broader Impact\n\nDemonstrating that a germline‑inspired autophagy boost can improve somatic healthspan would shift the focus from enhancing repair mechanisms to exploiting existing quality‑control pathways that the germline already uses. It would also provide a mechanistic basis for intermittent autophagy‑activating therapies aimed at delaying age‑related decline.
